Lin28B is an oncofetal circulating cancer stem cell-like marker associated with recurrence of hepatocellular carcinoma

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Cheng, Shu Wen ^a   Tsai, Hung Wen ^a,b,c   Lin, Yih Jyh ^a,b   Cheng, Pin Nan ^b,c   Chang, Yu Chung ^b   Yen, Chia Jui ^a,b   Huang, Hsuan Pang ^a   Chuang, Yun Pei ^b   Chang, Ting Tsung ^b,c   Lee, Chung Ta ^b   Chao, Anning ^d,e   Chou, Cheng Yang ^b   Chan, Shih Huang ^c   Chow, Nan Haw ^a,b   Ho, Chung Liang ^a,b,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CELL STRAIN HEPG2; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FETUS; FETUS (ANATOMY); GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIN28B GENE; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RECURRENCE FREE SURVIVAL; TISSUE SECTION; UPREGULATION; YOUNG ADULT;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATECTOMY; HOMEODOMAIN PROTEINS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; RNA, MESSENGER; RNA-BINDING PROTEINS; SOXB1 TRANSCRIPTION FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896703287     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080053     Document Type: Article

References (46)

1. el-Serag HB (2001) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 5: 87-107, vi doi:10.1016/S1089-3261(05)70155-0. PubMed: 11218921.
2. Cleynen I, Brants JR, Peeters K, Deckers R, Debiec-Rychter M et al. (2007) HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-kappaB. Mol Cancer Res 5: 363-372. doi:10.1158/1541-7786.MCR-06-0331. PubMed: 17426251. (Pubitemid 46706998)
3. Sarandakou A, Protonotariou E, Rizos D (2007) Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 44: 151-178. doi:10.1080/10408360601003143. PubMed: 17364691.
4. Hsu CC, Chiang CW, Cheng HC, Chang WT, Chou CY et al. (2011) Identifying LRRC16B as an oncofetal gene with transforming enhancing capability using a combined bioinformatics and experimental approach. Oncogene 30: 654-667. doi:10.1038/onc.2010.451. PubMed: 21102520.
5. Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA et al. (2009) Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A 106: 3384-3389. doi:10.1073/pnas. 0808300106. PubMed: 19211792.
6. Viswanathan SR, Daley GQ, Gregory RI (2008) Selective blockade of microRNA processing by Lin28. Science 320: 97-100. doi:10.1126/science.1154040. PubMed: 18292307. (Pubitemid 351490762)
7. Moss EG, Tang L (2003) Conservation of the heterochronic regulator Lin-28, its developmental expression and microRNA complementary sites. Dev Biol 258: 432-442. doi:10.1016/S0012-1606(03)00126-X. PubMed: 12798299. (Pubitemid 36683139)
8. Yamanaka S (2008) Pluripotency and nuclear reprogramming. Philos Trans R Soc Lond B Biol Sci 363: 2079-2087. doi:10.1098/rstb. 2008.2261. PubMed: 18375377.
9. Guo Y, Chen Y, Ito H, Watanabe A, Ge X et al. (2006) Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Gene 384: 51-61. doi:10.1016/j.gene. 2006.07.011. PubMed: 16971064.
10. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL et al. (2009) Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 41: 843-848. doi:10.1038/ng.392. PubMed: 19483683.
11. Wang YC, Chen YL, Yuan RH, Pan HW, Yang WC et al. (2010) Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. Carcinogenesis 31: 1516-1522. doi:10.1093/carcin/bgq107. PubMed: 20525879.
12. King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS et al. (2011) LIN28B promotes colon cancer progression and metastasis. Cancer Res 71: 4260-4268. doi:10.1158/1538-7445.AM2011-4260. PubMed: 21512136.
13. Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y et al. (2009) Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. Eur J Cancer 45: 2212-2218. doi:10.1016/j.ejca. 2009.05.003. PubMed: 19477633.
14. King CE, Wang L, Winograd R, Madison BB, Mongroo PS et al. (2011) LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. Oncogene 30: 4185-4193. doi:10.1038/onc.2011.131. PubMed: 21625210.
15. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z et al. (2010) Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLOS ONE 5: e12445. doi:10.1371/journal.pone.0012445. PubMed: 20805998.
16. Elshimali YI, Grody WW (2006) The clinical significance of circulating tumor cells in the peripheral blood. Diagn Mol Pathol 15: 187-194. doi: 10.1097/01.pdm.0000213463.98763.b9. PubMed: 17122646. (Pubitemid 44813657)
17. Ghossein RA, Bhattacharya S, Rosai J (1999) Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res 5: 1950-1960. PubMed: 10473071. (Pubitemid 29399243)
18. Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253: 180-204. doi:10.1016/j.canlet.2006.12.014. PubMed: 17314005. (Pubitemid 47017533)
19. Aerts J, Wynendaele W, Paridaens R, Christiaens MR, van den Bogaert W et al. (2001) A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol 12: 39-46. doi:10.1023/A: 1008317512253. PubMed: 11249047.
20. Andergassen U, Hofmann S, Kölbl AC, Schindlbeck C, Neugebauer J et al. (2013) Detection of Tumor Cell-Specific mRNA in the Peripheral Blood of Patients with Breast Cancer-Evaluation of Several Markers with Real-Time Reverse Transcription-PCR. Int J Mol Sci 14: 1093-1104. doi:10.3390/ijms14011093. PubMed: 23299436.
21. Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC et al. (2011) Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann Surg 254: 569-576. doi: 10.1097/SLA.0b013e3182300a1d. PubMed: 21892074.
22. Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N et al. (2011) Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 29: 1547-1555. doi:10.1200/JCO.2010.30.5151. PubMed: 21422427.
23. Wang TH, Chao A, Tsai CL, Chang CL, Chen SH et al. (2010) Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation. Mol Cell Proteomics 9: 1873-1884. doi:10.1074/mcp.M110.000802. PubMed: 20501939.
24. Pu YS, Huang CY, Chen JY, Kang WY, Lin YC et al. (2012) Down-regulation of PKCzeta in renal cell carcinoma and its clinicopathological implications. J Biomed Sci 19: 39. doi:10.1186/1423-0127-19-39. PubMed: 22475628.
25. Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ et al. (2013) MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis 34: 530-538. doi:10.1093/carcin/bgs371. PubMed: 23188675.
26. Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N et al. (2003) Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin Cancer Res 9: 5145-5151. PubMed: 14613993. (Pubitemid 37413564)
27. Radonić A, Thulke S, Mackay IM, Landt O, Siegert W et al. (2004) Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 313: 856-862. doi:10.1016/j.bbrc. 2003.11.177. PubMed: 14706621.
28. Yamashita T, Ji J, Budhu A, Forgues M, Yang W et al. (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136: 1012-1024. doi:10.1053/j.gastro.2008.12.004. PubMed: 19150350.
29. Kong QL, Hu LJ, Cao JY, Huang YJ, Xu LH et al. (2010) Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLOS Pathog 6: e1000940. PubMed: 20532215.
30. Tang B, Yoo N, Vu M, Mamura M, Nam JS et al. (2007) Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res 67: 8643-8652. doi:10.1158/0008-5472.CAN-07-0982. PubMed: 17875704. (Pubitemid 47437440)
31. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R et al. (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11: R46. doi:10.1186/bcr2333. PubMed: 19589136.
32. Méhes G, Witt A, Kubista E, Ambros PF (2001) Circulating breast cancer cells are frequently apoptotic. Am J Pathol 159: 17-20. doi:10.1016/S0002-9440(10)61667-7. PubMed: 11438448. (Pubitemid 33704186)
33. Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y et al. (2008) Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 14: 3306-3311. doi:10.1158/1078-0432.CCR-07-4749. PubMed: 18519757.
34. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715. doi:10.1016/j.cell.2008.03.027. PubMed: 18485877. (Pubitemid 351636299)
35. Dawood S, Broglio K, Valero V, Reuben J, Handy B et al. (2008) Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 113: 2422-2430. doi:10.1002/cncr.23852. PubMed: 18785255.
36. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791. doi:10.1056/NEJMoa040766. PubMed: 15317891. (Pubitemid 39095313)
37. Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J et al. (2007) Human hepatic stem cells from fetal and postnatal donors. J Exp Med 204: 1973-1987. doi:10.1084/jem.20061603. PubMed: 17664288. (Pubitemid 47236331)
38. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273. doi:10.1038/nrc2620. PubMed: 19262571.
39. Liu LL, Fu D, Ma Y, Shen XZ (2011) The Power and the Promise of Liver Cancer Stem Cell Markers. Stem Cells Dev 20: 2023-2030. doi:10.1089/scd.2011. 0012. PubMed: 21651381.
40. Crea F, Fornaro L, Masi G, Falcone A, Danesi R et al. (2011) Faithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics? J Clin Oncol 29: 3487-3490; author reply: 21788560.
41. Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M et al. (2002) alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 35: 853-860. doi:10.1053/jhep.2002.32100. PubMed: 11915031. (Pubitemid 34258379)
42. Louha M, Poussin K, Ganne N, Zylberberg H, Nalpas B et al. (1997) Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer. Hepatology 26: 998-1005. doi:10.1002/hep.510260430. PubMed: 9328326. (Pubitemid 27413670)
43. Minata M, Nishida N, Komeda T, Azechi H, Katsuma H et al. (2001) Postoperative detection of alpha-fetoprotein mRNA in blood as a predictor for metastatic recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol 16: 445-451. doi:10.1046/j. 1440-1746.2001.02461.x. PubMed: 11354284.
44. Wong IH, Lau WY, Leung T, Yeo W, Johnson PJ (1999) Hematogenous dissemination of hepatocytes and tumor cells after surgical resection of hepatocellular carcinoma: a quantitative analysis. Clin Cancer Res 5: 4021-4027. PubMed: 10632334. (Pubitemid 30013779)
45. Wu W, Yao DF, Yuan YM, Fan JW, Lu XF et al. (2006) Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 5: 538-544. PubMed: 17085339. (Pubitemid 44782093)
46. Aselmann H, Wolfes H, Rohde F, Frerker M, Deiwick A et al. (2001) Quantification of alpha 1-fetoprotein mRNA in peripheral blood and bone marrow: a tool for perioperative evaluation of patients with hepatocellular carcinoma. Langenbecks Arch Surg 386: 118-123. doi:10.1007/s004230000199. PubMed: 11374044.